Tardif, Jean-Claude; Bouabdallaoui, Nadia; L'allier, Philippe L; Gaudet, Daniel; Shah, Binita; Pillinger, Michael H; Lopez-Sendon, Jose; Luz, Protásio Lemos da 
; Verret, Lucie; Audet, Sylvia
Source: Lancet respiratory medicine. Unidade: FM
Subjects: COVID-19, INFLAMAÇÃO, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TARDIF, Jean-Claude et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, v. 9, n. 8, p. 924-932, 2021Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(21)00222-8. Acesso em: 10 jun. 2024.APA
Tardif, J. -C., Bouabdallaoui, N., L'allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., et al. (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, 9( 8), 924-932. doi:10.1016/S2213-2600(21)00222-8NLM
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8Vancouver
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8
